Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial
Autore:
Ciernik, IF; Schanz, U; Gmur, J;
Indirizzi:
Univ Zurich Hosp, Dept Internal Med, Div Hematol, Zurich, Switzerland UnivZurich Hosp Zurich Switzerland d, Div Hematol, Zurich, Switzerland
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 2, volume: 24, anno: 1999,
pagine: 147 - 151
SICI:
0268-3369(199907)24:2<147:DTWGCF>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
FACTOR ACCELERATES NEUTROPHIL; STEM-CELL TRANSPLANTATION; G-CSF; LEUKEMIA; DISORDERS; RECEPTOR; RECOVERY;
Keywords:
bone marrow transplantation; hematopoietic growth factors; G-CSF/granulocyte colony-stimulating factor; neutrophil engraftment; hematopoietic recovery;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Ciernik, IF CHU Vaudois, Ctr Pluridisciplinaire Oncol, Rue Bugnon 46, CH-1011 Lausanne, Switzerland CHU Vaudois Rue Bugnon 46 Lausanne Switzerland CH-1011 erland
Citazione:
I.F. Ciernik et al., "Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial", BONE MAR TR, 24(2), 1999, pp. 147-151

Abstract

The use of granulocyte colony-stimulating factor (G-CSF) has been established to improve hematological recovery after allogeneic bone marrow transplantation (BMT). The optimal timing to start with G-CSF has not been determined, This study investigates whether delayed use of G-CSF starting on day 6 is as safe and efficient as starting treatment with G-CSF immediately afterBMT. Thirty-eight patients undergoing allogeneic BMT were randomized to either receive post-transplant G-CSF treatment starting at day 1 or at day 6. The time to hematological recovery was monitored and the groups were compared with respect to peritransplant morbidity and mortality. Recovery of theneutrophil granulocyte counts (PMN) to >100/mu l, >500/mu l and >1000/mu lwas comparable in both groups, The nadir of the PMN counts after stopping G-CSF was also similar. There was no difference in the recovery of red blood cells and platelet counts and no difference between the two groups with respect to the number of febrile episodes, number of days with antibiotics or number of documented bacterial, fungal or viral infections, Delayed treatment with G-CSF resulted in a reduction of G-CSF treatment from 19 days to 14 days (P = 0.0017), Reducing the length of treatment by 5 days lowered G-CSF treatment costs by 26.3%, Therefore, postponing treatment,vith G-CSF has no influence on the hematological recovery after allogeneic BMT, There isan economical benefit of postponing G-CSF use without any clinical disadvantages.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:01:53